How can heart failure advocates in Spain seize current opportunities to improve care?

News & Events

22 September 2022
AUTHOR: HFPN Admin

 

This year, Spain has become one of the few countries in Europe with a national strategy on cardiovascular health that prioritises heart failure among other conditions. But how heart failure can advocates fully seize this and other key opportunities to ensure national recommendations and targets for heart failure care are implemented at the local level?

Our latest policy brief attempts to answer this question, examining existing opportunities and mechanisms to advocate for guideline-recommended care in Spain.  This includes securing regional funding from organisations driving digital transformation, or calling on regional technology assessment agencies collecting heart failure data to provide policy recommendations.

This briefing is the first in our new series, From guidelines to action: opportunities for heart failure advocacy, which aims to equip advocates with a targeted analysis of the opportunities available in their countries and specific actions to take forward. These actions were developed based on successful examples from a number of health advocacy areas and interviews with national heart failure experts. Upcoming reports will focus on France, Germany and Italy.

Download the report

Tagged:

More from News & Events

The Heart Failure Policy Summit returns in April 2024 to bri
The Heart Failure Policy Summit returns in April 2024 to bri...
18 January 2024
This April, the HFPN is delighted to host the Heart Failure Policy Summit 2024....
Read article
Five lessons from the European Heart Failure Mission launch
Five lessons from the European Heart Failure Mission launch ...
15 November 2023
In October 2023, the HFPN launched the European Heart Failure Mission Statement at the European Parliament. Here's five things we learned....
Read article
The Heart Failure Policy Network is an independent, multidisciplinary platform made possible with financial support from AstraZeneca and Roche Diagnostics. The content produced by the Network is not biased toward any specific treatment or therapy. All outputs are guided and endorsed by the Network’s members. All members provide their time for free. The Network is hosted by The Health Policy Partnership .